Department of Pharmaceutical Biotechnology, Faculty of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.
Department of Genetics and Molecular Biology, Faculty of Medicine, Isfahan University of Medical Science, Isfahan, Iran.
CNS Neurol Disord Drug Targets. 2018;17(7):496-508. doi: 10.2174/1871527317666180713111100.
BACKGROUND & OBJECTIVE: Multiple sclerosis is an autoimmune demyelinating disease of the human central nervous system with still unknown etiology. Infiltration, accumulation and activation of autoreactive T cells, macrophages and other inflammatory immune cells in the CNS are the crucial steps in MS neuropathogenesis and development. Chemokines and their receptors play the main role in the attraction of the pathogenic cells into the CNS in MS. Specific chemokines and chemokine receptors are up-regulated in the actively demyelinating lesions and cerebrospinal fluid of MS patients. Many medical studies investigated how changes in levels or activities of chemokines and their receptors are implicated in leukocyte migration into CNS and consequently causing MS. These chemokines and their receptors are under intense focus to introduce new therapeutic strategies for MS.
The aim of this review is to summarize previous findings on the relationship between chemokines network and MS development. Furthermore, opportunities and challenges in the chemokine system intervention as a potential therapeutic target for the treatment of MS will be outlined.
多发性硬化症是一种人类中枢神经系统的自身免疫性脱髓鞘疾病,其病因仍不清楚。在 MS 发病机制和发展过程中,自身反应性 T 细胞、巨噬细胞和其他炎症免疫细胞在中枢神经系统中的浸润、聚集和激活是关键步骤。趋化因子及其受体在 MS 中致病性细胞进入中枢神经系统的吸引中起主要作用。在 MS 患者的活动脱髓鞘病变和脑脊液中,特定的趋化因子及其受体上调。许多医学研究调查了趋化因子及其受体水平或活性的变化如何与白细胞向中枢神经系统迁移有关,进而导致多发性硬化症。这些趋化因子及其受体是目前研究的重点,旨在为多发性硬化症提供新的治疗策略。
本文综述了趋化因子网络与多发性硬化症发展之间关系的研究进展。此外,还概述了趋化因子系统干预作为多发性硬化症治疗潜在治疗靶点的机遇和挑战。